Announced Date: 2025-08-19 (August 19, 2025)
Asset Name: RC28-E Intravitreal Injection
Licensor: RemeGen (RemeGen Co., Ltd., China)
Licensee (Buyer): Santen（Santen Pharmaceutical Co., Ltd，Japan; Santen Pharmaceutical (China) Co. Ltd.）
Asset Target: Vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF).
Asset Modality: Bi-specific fusion protein drug
Current Stage: Phase III, China
.
Scope of Authority:
RemeGen has granted Santen a paid license for its proprietary RC28-E intravitreal injection. Santen has obtained exclusive rights to develop, manufacture, and commercialize RC28-E within the following business territories: Mainland China, Taiwan, Hong Kong, Macau, South Korea, Thailand, Vietnam, Singapore, the Philippines, Indonesia, and Malaysia.
.
Deal Detail:
Upfront payment of RMB 250 million;
Development and regulatory milestone payments up to RMB 520 million;
Sales milestone payments of up to RMB 525 million;
Additional royalties based on net sales in the licensed territories.
Total RMB 1.295 billion plus
.
Link:
Santen Announces New Licensing Agreement with RemeGen for RC28-E Intravitreal Injection, an Anti-VEGF/FGF Dual-Target Fusion Protein
